Astrocyte Pharmaceuticals Inc. announced initiation of a phase 1b study of AST-004, a small molecule adenosine A3/A1 receptor agonist for stroke and traumatic brain injuries that will be evaluated in healthy volunteers.According to a release from Astrocyte, the study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AST-004 as a loading dose followed by continuous